UK: Painful Outcome For Warner-Lambert: UK Supreme Court Dismisses Appeal In Medical Use Of Pregabalin Patent Dispute

Last Updated: 22 November 2018
Article by Barbara Rigby

On 14 November 2018 the UK Supreme Court (SC) handed down its decision in Warner-Lambert Company LLC v Generics (UK) Ltd t/a Mylan and Actavis, which includes a majority judgment and interesting dissenting ones. 

The key claims were held to be invalid for lack of sufficiency, confirming the role of 'plausibility' in the assessment of sufficiency, although there was disagreement over how high the plausibility threshold should be. 

The SC also indicated that if valid, these claims would not have been infringed, but could not agree unanimously on the correct test for infringement of Swiss-type second medical use claims.

Background to the Appeal

Warner-Lambert has a second medical use patent, EP0934061, directed to the medical use of pregabalin for the treatment of pain (claim 1), inflammatory pain (claim 2) and neuropathic pain (claim 3). The claims are in the old Swiss-type medical use format. An earlier patent directed to pregabalin has expired.

Pregabalin is authorised for the treatment of peripheral and central neuropathic pain, epilepsy and generalised anxiety disorder and Warner-Lambert markets the drug under the brand name Lyrica.

Several generics companies, referred to herein collectively as 'Actavis', launched the drug under a 'skinny label' for the off-patent indications epilepsy and generalised anxiety disorder. However, Warner-Lambert sought to assert EP0934061, alleging that the skinny label would not prevent infringing uses of the drug. In return, Actavis sought revocation of the patent for lack of inventive step and sufficiency. An intricate legal battle ensued.

The first instance court rejected the arguments based on lack of inventive step and these were not at issue before the SC. Instead, validity turned on the issue of sufficiency.

Claim 1 was construed as extending to all pain and Claim 3 as extending to all neuropathic pain. These claims failed for insufficiency because the first instance court held that whilst there was sufficient disclosure in the specification to support the claim that pregabalin was efficacious in the treatment of inflammatory and peripheral neuropathic pain, this was not the case for central neuropathic pain. An application to amend claim 3 to limit it peripheral neuropathic pain was rejected as an abuse of process. These findings were upheld on Appeal.

With regard to infringement, the judges proposed different approaches as to how infringement of Swiss-type claims should be assessed.

The trial judge applied a test of "subjective intent", namely that the manufacturer must make the product with the intention of targeting the patent-protected market. In contrast, the Court of Appeal applied a test of "objective intent", which asks whether the alleged infringer knew or could foresee  that at least some of the prescriptions for the claimed drug for the claimed indication would in fact be fulfilled with the generic drug. The absence of the claimed indication from the 'skinny' label could not "conceivably be sufficient to negative the intention". Instead, the test will be negative where the manufacturer has "taken all reasonable steps within his power to prevent the consequences occurring".

Thus, the SC had to consider the following key issues: (i) the construction of the claims, amendment and abuse of process; (ii) the sufficiency of the disclosure in the specification; and (iii) ; and the test for infringement of a Swiss-style medical use patent claim.

The Supreme Court judgement

Construction, amendment and abuse of process

The SC unanimously affirms that claim 1 extends to all pain and claim 3 to all neuropathic pain, whether peripheral or central.

Warner-Lambert's application to limit claim 3 to peripheral neuropathic pain is rejected as an abuse of process.


There has been significant debate over whether the non-statutory 'plausibility' test should play a role in the assessment of sufficiency.

The SC judgment confirms that plausibility is a threshold test that must be used to assess whether a second medical use claim meets the requirement of sufficiency.

The claims at issue were found to be insufficient in relation to neuropathic pain.

Interestingly, the SC judges could not reach agreement on the correct standard for plausibility. The dissenting judges propose a very low standard of plausibility, but the majority's approach requires the patentee to demonstrate that the specification discloses some scientific reason why the implied assertion of efficacy in the patent claim may well be true [36-37].


The SC judges agree that if claims 1 and 3 had been valid, they would not have been infringed by Actavis, but they differ substantially in their reasons for arriving at this result.

Lord Sumption and Lord Reed consider that the intention of the alleged infringer, whether subjective or objective, is irrelevant. Thus, they propose the "outward presentation" test, under which the sole criterion of infringement is whether the product as it emerges from the manufacturing process, including any labelling or accompanying leaflet, is presented as suitable for the uses which enjoy patent protection [71-86].

Lord Mance agrees that the test depends on the objective appearance and characteristics of the product as it is prepared, presented and put on the market, but considers that in rare cases the context may make it obvious that these are not to be taken at face value [218-223].

Lord Briggs and Lord Hodge consider that the test should be whether the alleged infringer subjectively intended to target the patent-protected market.


Given that the claims at issue were held to be invalid, the SC's opinions on infringement are orbiter and thus non-binding. We will therefore have to await future judgments to receive binding guidance on the issue of infringement of Swiss-style medical use claims.

It is also worth bearing in mind that the Warner-Lambert claims were in the Swiss-style format, i.e. they were purpose-limited process  claims. Second medical use inventions must now be claimed in Europe in the form of purpose-limited product  claims (the 'EPC2000' format). The test for infringement of purpose-limited product  claims will necessarily differ.

It is clear that to avoid infringement of a Swiss-style claim in the UK, a generic product should not identify in its packaging, labelling or patient instruction leaflet any potential uses which are subject to patent protection. However, this alone may not necessarily guarantee a finding of non-infringement in the UK.  Of course, it must also be borne in mind that there is no harmonised approach to the assessment of infringement throughout Europe.   

Please click here to view the original article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions